CRBP
NASDAQ
US
Corbus Pharmaceuticals Holdings, Inc. - Common Stock
$10,17
▲ +$0,19
(+1,90%)
Vol 236K
2
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$142.9M
ROE
-57,1%
Margin
-2838,7%
D/E
0,00
Beta
2,86
52W
$5–$21
Konsensus Wall Street
16 analis · Apr 20266
Beli Kuat
9
Beli
1
Tahan
0
Jual
0
Jual Kuat
93,8%
Peringkat Beli
Grafik Harga
Saham Serupa
ELTX
Elicio Therapeutics Inc
$139.2M
ZNTL
Zentalis Pharmaceuticals Inc
$97.5M
MGNX
MacroGenics Inc
$101.8M
CRBU
Caribou Biosciences Inc
$148.6M
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
GALT
Galectin Therapeutics Inc
$268.2M
ACHV
Achieve Life Sciences Inc
$264.6M
SGMT
Sagimet Biosciences Inc
$183.5M
CNTN
Canton Strategic Holdings Inc
Pendapatan
Tingkat beat: 50,0%| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Des 2025 | $-1,61 | $-1,25 | +$0,36 |
| Sep 2025 | $-1,74 | $-1,90 | $-0,16 |
| Jun 2025 | $-1,54 | $-1,44 | +$0,10 |
| Mar 2025 | $-1,31 | $-1,39 | $-0,08 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Pendapatan | — | — | — | — | — |
| Laba Bersih | -$13.8M | -$9.5M | -$17.0M | -$17.7M | -$23.3M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -43.6% | -43.6% | -43.6% | -43.6% | -43.6% | -57.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -2838.7% | -2838.7% | -2838.7% | -2838.7% | -2838.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 | 6.31 |
Rasio Utama
ROA (TTM)
-50,9%
P/S (TTM)
92,18
P/B
1,0
EPS (TTM)
$-5,51
CF/Share
$-10,98
52W High
$20,56
52W Low
$4,64
$4,64
Rentang 52 Minggu
$20,56
Kesehatan Keuangan
Arus Kas Bebas
-$15.6M
Utang Bersih
-$24.9M
Kas
$27.0M
Total Utang
$2.0M
Per tanggal Sep 30, 2025
Як CRBP виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CRBP vs аналоги Biotechnology
P/E
—
▼
0%
di bawah
rekan
(18,8)
vs Rekan
vs Industri
Undervalued
P/S
92,2
▲
617%
di atas
rekan
(12,9)
vs Rekan
vs Industri
Lebih mahal
P/B
1,0
▼
59%
di bawah
rekan
(2,5)
vs Rekan
vs Industri
Undervalued
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість CRBP vs аналоги Biotechnology
ROE
-57,1%
▲
15%
di atas
rekan
(-67,3%)
vs Rekan
vs Industri
Sejajar
Net margin
-2838,7%
▼
890%
di bawah
rekan
(-286,8%)
vs Rekan
vs Industri
Lemah
Валова маржа
—
▼
0%
di bawah
rekan
(78,6%)
vs Rekan
vs Industri
Sejajar
ROA
-50,9%
▼
9%
di bawah
rekan
(-46,7%)
vs Rekan
vs Industri
Sejajar
Фінансове здоровʼя CRBP vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
di bawah
rekan
(0,0)
vs Rekan
vs Industri
Utang rendah
Поточна ліквідність
6,3
▲
42%
di atas
rekan
(4,4)
vs Rekan
vs Industri
Di bawah rata-rata
Beta
2,9
▲
195%
di atas
rekan
(1,0)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів CRBP
CRBP
Median rekan
Industri
CRBP прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CRBP vs аналоги: ключові метрики
Aktivitas Orang Dalam
NeutralPembelian
0
Penjualan
0
SMETHURST DOMINIC
Officer · Mar 02
6097 shs
HODGSON IAN
Chief Operating Officer · Feb 17
847 shs
MORAN SEAN F
Chief Financial Officer · Feb 13
4701 shs
COHEN YUVAL
Chief Executive Officer · Feb 13
13871 shs
SMETHURST DOMINIC
Officer · Feb 03
3285 shs
HODGSON IAN
Chief Operating Officer · Feb 03
2415 shs
MORAN SEAN F
Chief Financial Officer · Jan 14
28082 shs
COHEN YUVAL
Chief Executive Officer · Jan 14
50000 shs
SMETHURST DOMINIC
Officer · Jan 14
28365 shs
HODGSON IAN
Chief Operating Officer · Jan 14
28365 shs
Terakhir 90 hari
Pemegang Terbesar
Top 5: 39,91%Cormorant Asset Management,…
13,22%
$20.4M
Orbimed Advisors LLC.
9,01%
$13.9M
Aberdeen Group plc
7,45%
$11.5M
Octagon Capital Advisors LP
5,38%
$8.3M
Vanguard Group Inc
4,85%
$7.5M
Per tanggal Des 31, 2025
Berita Terbaru
Belum ada berita terkait